KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $562.7 million.

  • Royalty Pharma's Cash from Financing Activities rose 272.88% to $562.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 395.53%. This contributed to the annual value of $361.1 million for FY2024, which is 116.81% up from last year.
  • Per Royalty Pharma's latest filing, its Cash from Financing Activities stood at $562.7 million for Q3 2025, which was up 210.82% from -$507.8 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Cash from Financing Activities high stood at $1.2 billion for Q2 2024, and its period low was -$1.4 billion during Q3 2023.
  • For the 3-year period, Royalty Pharma's Cash from Financing Activities averaged around -$243.1 million, with its median value being -$258.0 million (2024).
  • As far as peak fluctuations go, Royalty Pharma's Cash from Financing Activities plummeted by 490.86% in 2023, and later soared by 433.32% in 2024.
  • Over the past 5 years, Royalty Pharma's Cash from Financing Activities (Quarterly) stood at -$198.1 million in 2021, then slumped by 34.07% to -$265.6 million in 2022, then rose by 12.67% to -$231.9 million in 2023, then declined by 11.24% to -$258.0 million in 2024, then soared by 272.88% to $562.7 million in 2025.
  • Its last three reported values are $562.7 million in Q3 2025, -$507.8 million for Q2 2025, and -$941.3 million during Q1 2025.